Anti-herpesvirus agents: a patent and literature review (2003 to present) [0.03%]
抗疱疹病毒药物的专利和文献回顾（2003至现在）
Marcin Skoreński,Marcin Sieńczyk
Marcin Skoreński
Introduction: The standard therapy used to treat herpesvirus infections is based on the application of DNA polymerase inhibitors such as ganciclovir or aciclovir. Unfortunately, all of these compounds exhibit relatively h...
Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013) [0.03%]
诱导性酪氨酸激酶抑制剂专利文献综述(2010-2013)
Peter Norman
Peter Norman
Introduction: The non-receptor tyrosine kinase, inducible tyrosine kinase (Itk), plays an important role in thymus(T)-cell signalling and the production of pro-inflammatory cytokines. Itk, and the other Tec family members...
Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013) [0.03%]
极光激酶抑制剂专利及其临床检测状况(2011-2013)
Chun Hei Antonio Cheung,Sailu Sarvagalla,Jane Ying-Chieh Lee et al.
Chun Hei Antonio Cheung et al.
Introduction: Aurora kinase A, B and C, members of serine/threonine kinase family, are key regulators of mitosis. As Aurora kinases are overexpressed in many of the human cancers, small-molecule inhibitors of Aurora kinas...
Changes to intellectual property policy in South Africa: putting a stop to evergreening? [0.03%]
南非知识产权政策的变化：“叫停”专利续期行为？
Julia E Hill
Julia E Hill
South Africa is a middle-income country with the world's largest HIV patient cohort and a growing burden of communicable and non-communicable diseases - a prime location for pharmaceutical companies looking to expand their markets. Yet, 20 ...
Parkinson's disease biomarker: a patent evaluation of WO2013153386 [0.03%]
帕金森病生物标志物：评估WO201315386专利
Werner J Geldenhuys,Samir M Abdelmagid,Patrick J Gallegos et al.
Werner J Geldenhuys et al.
Introduction: Parkinson's disease (PD) is a neurodegenerative movement disorder resultant from the loss of dopaminergic neurons in the brain. There is an urgent need for effective biomarkers that can be used in the early ...
Natércia F Brás,Nuno Mfsa Cerqueira,Maria J Ramos et al.
Natércia F Brás et al.
Introduction: In the recent decades, the interest on glycosidases has dramatically increased, mainly because these enzymes play a key role in many biological processes. The importance of these enzymes is also reflected by...
Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013) [0.03%]
关于LRRK2抑制剂专利的综述(2011-2013)
Raghava R Kethiri,Rajagopal Bakthavatchalam
Raghava R Kethiri
Introduction: Leucine-rich repeat kinase 2 (LRRK2) is a large (2527 residues) complex multi-domain protein that has GTPase and kinase domains. Autosomal dominant missense mutations in LRRK2 have been found in individuals ...
René Csuk
René Csuk
Introduction: Betulinic acid (BA) is a triterpenoid that can be obtained from renewable resources. BA is cytotoxic to many human tumor cell lines mainly by apoptosis but cell death might also be triggered by nonapoptotic ...
Anticancer patent landscape and technology assessment of Indian public-funded research institutes and organizations [0.03%]
印度公立机构抗癌专利和技术评估报告
Ajay Dara,Abhay T Sangamwar
Ajay Dara
Introduction: This review discusses the various drug therapeutic targets and latest technologies of anticancer patents from 10 Indian public-funded research organizations covering more than 150 esteemed institutes. We hav...
Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease? [0.03%]
不断增加的新开发的富亮氨酸重复激酶2抑制剂能否验证或证伪帕金森病的潜在疾病修饰治疗策略？
Jean-Marc Taymans
Jean-Marc Taymans
Leucine-rich repeat kinase 2 (LRRK2) is considered an attractive therapeutic target for potential disease-modifying treatment of Parkinson's disease (PD). Both genetic and cell biological evidence have contributed to the hypothesis that LRR...